Article and Video CATEGORIES
Here's a recent video podcast I just did on the publication just out in Lancet Oncology, describing a randomized phase II study led by my friend Pasi Janne, from Dana Farber Cancer Institute in Boston.
[powerpress]
We've touched on this study before, but it's promising enough for the field of lung cancer that it should be covered as the publication comes out, especially since KRAS mutations are actually the most common molecular defect we see in NSCLC, and yet we haven't had an actual treatment to offer such patients in the past. Let's hope this work leads that to change soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...
Hi and welcome to GRACE. I'm sorry to know you are entering a new stage. I'm not about to comment just now but wanted to let you know I see your...
Edit to say, we can't give advice but we can comment with views and facts. :)
My first thought is to ask if she has been seen at a large...
Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...
Thank you, Janine, for answering so rapidly. I am aware that my nodules are small, but they scare me all the same. Your words that nodule measurements may vary somewhat when...
Hi Barbro, I'm sorry you're worrying about this, and don't feel like you can discuss this with your doctor. Speak to your doctor about this. Let them know your worries and...
Hi Bluebird, Welcome to GRACE. I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had.
A CT would be...